ReviewChinese medicine2026
Pharmacological intervention of Chinese medicine via regulating ferroptosis in gastric cancer.
Review in Chinese medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Gastric cancer (GC) is the second most frequently diagnosed malignancy, as well as the second most common cause of cancer-related deaths in China. Drug resistance is a major factor that limits the efficacy of GC chemotherapy. Given the increased resistance of GC cells to ferroptosis, activating the ferroptotic pathways has emerged as a promising therapeutic strategy against GC. This review summarizes the pathways involved in ferroptosis resistance in GC cells and the mechanisms underlying the therapeutic effects of herbal formulae and their bioactive compounds, with particular emphasis on ferroptosis. Multiple signaling pathways are implicated in regulating ferroptosis in GC cells, including the Wnt/β-catenin, PI3K/AKT/mTOR, TGF-β1/Smad, NF-κB, and Hippo pathways. According to previous clinical trials, traditional Chinese medicine (TCM) formulations can prolong the survival or increase survival chances in patients with GC, and reduce adverse reactions, thereby improving the quality of life. Finally, preclinical studies have shown TCMs and their bioactive compounds can ameliorate GC progression by triggering ferroptosis. Despite these beneficial effects on patients with GC, the underlying molecular mechanisms of TCM in GC have not been fully elucidated yet, and there are also some crucial shortcomings in the current studies. Therefore, further clinical trials and experimental studies are required to deepen our understanding of the mechanisms for activating ferroptosis in GC cells through TCM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.